MALLINCKRODT UK LTD

• ◆

  1 PSC ceased in last 24 months

  Significant control changed hands — see the Ownership section.

1. MALLINCKRODT UK LTD 1995-10-02 → present
2. PURITAN-BENNETT UK LIMITED 1986-06-23 → 1995-10-02

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

Accounting basis

FRS 102

Reporting scope

Standalone (parent only)

Auditor

PricewaterhouseCoopers

Audit opinion

Unqualified (clean)

Going concern

Affirmed

“The Directors are preparing the financial statements on a going concern basis. Further details are provided in note 1. Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.”

Group structure

1. MALLINCKRODT UK LTD · parent
   1. Mallinckrodt Pharmaceuticals Limited 100% · UK · to develop, manufacture, market and distribute specialty pharmaceutical products and therapies.
   2. Mallinckrodt Medical Holdings (UK) Limited 100% · UK · holding company. It also provides services to other group companies.
   3. Mallinckrodt ARD Holdings (UK) Limited 100% · UK · holding company.

Significant events

• “On 29 November 2024, the Mallinckrodt group sold the Therakos business to CVC Capital Partners Fund IX. This sale included the transfer of Therakos UK Limited, a subsidiary of Mallinckrodt UK Limited for $6,012,511.”
• “On 23 May 2024, the company received a dividend of $708,016,578 from Mallinckrodt ARD Holdings (UK) Limited a direct subsidiary.”
• “On 27 November 2024, the company received a distribution of $6,800,000 from Therakos UK Limited, a direct subsidiary. A second distribution, equivalent to $3,331,040 was received on 29 November 2024 from Therakos UK Limited. Following these distributions, the company undertook a review of the carrying value in Therakos UK Limited and based on this review, recorded an impairment of $4,673,599.”
• “On 13 March 2025, Mallinckrodt announced that they have entered into a definitive agreement to combine in a stock and cash transaction to create a global, scaled, diversified pharmaceuticals leader with Endo, Inc. The agreement is subject to shareholder/regulatory approvals.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

8

last 12 months

Capital events

0

last 24 months

Officers appointed

0

last 12 months

Officers resigned

0

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.

• Turnover

  —

  Not reported

• Cash

  +199.9%

  £1,483 → £4,448

• Net assets

  +6%

  £585,131,208 → £620,390,660

• Employees

  —

  Not reported

• Operating profit

  +67,842%

  -£40,030 → £27,117,124

• Profit before tax

  +1,189,288.9%

  -£2,965 → £35,259,451

Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers